WO2012138254A3 - Производные 4,4 '-бифенил амидов, обладающие фармакологической активностью, и лекарственные средства на их основе - Google Patents

Производные 4,4 '-бифенил амидов, обладающие фармакологической активностью, и лекарственные средства на их основе Download PDF

Info

Publication number
WO2012138254A3
WO2012138254A3 PCT/RU2012/000238 RU2012000238W WO2012138254A3 WO 2012138254 A3 WO2012138254 A3 WO 2012138254A3 RU 2012000238 W RU2012000238 W RU 2012000238W WO 2012138254 A3 WO2012138254 A3 WO 2012138254A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmacologically active
drugs based
biphenylamide
derivatives
neurodegenerative diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2012/000238
Other languages
English (en)
French (fr)
Other versions
WO2012138254A2 (ru
Inventor
Максим Эдуардович ЗАПОЛЬСКИЙ
Николай Серафимович ЗЕФИРОВ
Владимир Александрович ПАЛЮЛИН
Мстислав Игоревич ЛАВРОВ
Алексей Сергеевич МОРОЗОВ
Вера Леонидовна ЛАПТЕВА
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2012138254A2 publication Critical patent/WO2012138254A2/ru
Publication of WO2012138254A3 publication Critical patent/WO2012138254A3/ru
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к медицине и фармакологии. Новые производные 4,4' - бифениламидов, обладают фармакологической активностью и могут быть использованы в качестве новых эффективных аллостерических модуляторов АМРА рецепторов для лечения болезни Альцгеймера, болезни Паркинсона и других нейродегенеративных патологий. Заявлены также лекарственные средства для лечения когнитивных нарушений, для лечения расстройств поведения и настроения, дефицитарньгх психических нарушений, синдрома Attention Deficit Hyperactivity Disorder и других нейродегенеративных патологий.
PCT/RU2012/000238 2011-04-06 2012-04-02 Производные 4,4 '-бифенил амидов, обладающие фармакологической активностью, и лекарственные средства на их основе Ceased WO2012138254A2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2011113045/15A RU2456266C1 (ru) 2011-04-06 2011-04-06 Производные 4,4'-бифениламидов, обладающие фармакологической активностью, и лекарственные средства на их основе
RU2011113045 2011-04-06

Publications (2)

Publication Number Publication Date
WO2012138254A2 WO2012138254A2 (ru) 2012-10-11
WO2012138254A3 true WO2012138254A3 (ru) 2012-12-13

Family

ID=46847377

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2012/000238 Ceased WO2012138254A2 (ru) 2011-04-06 2012-04-02 Производные 4,4 '-бифенил амидов, обладающие фармакологической активностью, и лекарственные средства на их основе

Country Status (2)

Country Link
RU (1) RU2456266C1 (ru)
WO (1) WO2012138254A2 (ru)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110173A2 (en) * 2004-10-05 2006-10-19 Smithkline Beecham Corporation Novel compounds
WO2007031791A1 (en) * 2005-09-16 2007-03-22 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
WO2010137351A1 (en) * 2009-05-29 2010-12-02 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
RU2009126653A (ru) * 2009-07-14 2011-01-20 Учреждение Российской Академии наук Институт физиологически активных веществ РАН (ИФАВ РАН) (RU) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n,n'-замещенных 3,7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201041580A (en) * 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110173A2 (en) * 2004-10-05 2006-10-19 Smithkline Beecham Corporation Novel compounds
WO2007031791A1 (en) * 2005-09-16 2007-03-22 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
WO2010137351A1 (en) * 2009-05-29 2010-12-02 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
RU2009126653A (ru) * 2009-07-14 2011-01-20 Учреждение Российской Академии наук Институт физиологически активных веществ РАН (ИФАВ РАН) (RU) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n,n'-замещенных 3,7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения

Also Published As

Publication number Publication date
RU2456266C1 (ru) 2012-07-20
WO2012138254A2 (ru) 2012-10-11

Similar Documents

Publication Publication Date Title
WO2014037416A3 (en) Compositions for treating parkinson's disease
PH12017502351A1 (en) 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
MY195948A (en) Allosteric Modulators of Nicotinic Acetylcholine Receptors
JO3146B1 (ar) مشتقات غير متجانسة الحلقية و استخدامها في علاج الاضطرابات العصبية
MD20150023A2 (ru) Новые бициклические пиридиноны
TW201144302A (en) 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
UA109260C2 (uk) Хромонові похідні, спосіб їх одержання та їх терапевтичні застосування
WO2013170072A3 (en) Compounds for the treatment of neurological disorders
CL2015000096A1 (es) Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
PH12014501079A1 (en) 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions
TN2015000018A1 (en) 5-ht3 receptor antagonists
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
IL237332A0 (en) Pyrazole carboxamide derivatives as taar modulators for use in the treatment of serious diseases such as depression, diabetes and Parkinson's disease
IN2014DN11027A (ru)
WO2012061019A3 (en) Tricyclic mglur5 receptor modulators
HK1201523A1 (en) Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a
PH12015500496A1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
WO2012058128A3 (en) Caprolactam mglur5 receptor modulators
WO2011123842A9 (en) Methods for treating parkinson's disease and other disorders of dopaminergic neurons of the brain
AU2019268209A1 (en) Compounds for the treatment of seizures and other central nervous system disorders and conditions
WO2012138254A3 (ru) Производные 4,4 '-бифенил амидов, обладающие фармакологической активностью, и лекарственные средства на их основе
EA201301135A1 (ru) Трициклические производные n,n'-замещенных 3,7-диазабицикло[3.3.1]нонанов и лекарственные средства на их основе
HK1202117A1 (en) Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an so2-containing group as vanilloid receptor ligands
WO2014073994A3 (en) New alkanolamide derivatives of cinnamic acid and use of alkanolamide derivatives of cinnamic acid for preparation of drugs

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12767633

Country of ref document: EP

Kind code of ref document: A2